This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Motzer RJ , Tannir NM , McDermott DF , Aren Frontera O , Melichar B , Choueiri TK , Plimack ER , Barthelemy P , Porta C , George S , Powles T , Donskov F , Neiman V , Kollmannsberger CK , Salman P , Gurney H , Hawkins R , Ravaud A , Grimm MO , Bracarda S , Barrios CH , Tomita Y , Castellano D , Rini BI , Chen AC , Mekan S , McHenry MB , Wind-Rotolo M , Doan J , Sharma P , Hammers HJ , Escudier B
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
N Engl J Med. 2018 Apr 5;378(14) :1277-1290
PMID: 29562145 PMCID: PMC5972549 URL: https://www.ncbi.nlm.nih.gov/pubmed/29562145
AbstractBackground Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. Methods We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level,0.04), objective response rate (alpha level,0.001), and progression-free survival (alpha level,0.009) among patients with intermediate or poor prognostic risk. Results A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. Conclusions Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Notes1533-4406 Motzer, Robert J Tannir, Nizar M McDermott, David F Aren Frontera, Osvaldo Melichar, Bohuslav Choueiri, Toni K Plimack, Elizabeth R Barthelemy, Philippe Porta, Camillo George, Saby Powles, Thomas Donskov, Frede Neiman, Victoria Kollmannsberger, Christian K Salman, Pamela Gurney, Howard Hawkins, Robert Ravaud, Alain Grimm, Marc-Oliver Bracarda, Sergio Barrios, Carlos H Tomita, Yoshihiko Castellano, Daniel Rini, Brian I Chen, Allen C Mekan, Sabeen McHenry, M Brent Wind-Rotolo, Megan Doan, Justin Sharma, Padmanee Hammers, Hans J Escudier, Bernard CheckMate 214 Investigators Journal Article United States N Engl J Med. 2018 Mar 21. doi: 10.1056/NEJMoa1712126.